Skip to main navigation
Skip to search
Skip to main content
Northern Arizona University Home
Home
Profiles
Departments and Centers
Scholarly Works
Activities
Grants
Datasets
Prizes
Search by expertise, name or affiliation
Strategic combinations: The future of oncolytic virotherapy with reovirus
Xing Zhao
, Cariad Chester
, Narendiran Rajasekaran
, Zhixu He
, Holbrook E. Kohrt
Research output
:
Contribution to journal
›
Review article
›
peer-review
55
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Strategic combinations: The future of oncolytic virotherapy with reovirus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Activated Cells
16%
Activated Ras
16%
Anti-tumor Response
16%
Cancer Cells
16%
Cancer Treatment
16%
Chemotherapy
33%
Clinical Development
16%
Clinical Outcomes
16%
Combinational Therapy
16%
Double Strand
16%
Drug-resistant Tumor
16%
Efficacy-toxicity
16%
Human Cancer
16%
Human RNA Virus
16%
Human Tumors
16%
Immune Surveillance
16%
Immunosuppressive Mechanisms
16%
Lysis
16%
Multikinase Inhibitor
16%
Novel Therapeutics
16%
Oncogene
16%
Oncolytic Viral Therapy
33%
Oncolytic Virotherapy
100%
Phase II Trial
16%
Radiotherapy
33%
RAS Gene
16%
RAS Pathway
16%
Ras Signaling
16%
Reovirus
100%
Therapeutic Development
16%
Therapeutic Strategies
16%
Transformed Cells
16%
Treatment Modalities
16%
Treatment Progress
16%
Treatment-resistant
16%
Tumor
16%
Tumor Subclones
16%
Medicine and Dentistry
Cancer Cell
16%
Cancer Therapy
16%
Immunosuppressive Drug
16%
Immunosurveillance
16%
Immunotherapy
16%
Malignant Neoplasm
16%
Neoplasm
50%
Oncogene
16%
Oncogene Ras
16%
Oncolytic Virotherapy
100%
Phosphotransferase Inhibitor
16%
Radiation Therapy
33%
Ras Signaling
50%
Reoviridae
100%
Signal Transduction
16%
Transformed Cell
16%
Virus RNA
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
33%
Immunosuppressive Agent
16%
Immunotherapy
16%
Malignant Neoplasm
50%
Neoplasm
50%
Phosphotransferase Inhibitor
16%
Reoviridae
100%
Virotherapy
100%
Virus RNA
16%